Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2021-03-29 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
监事会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jinling Pharmaceutical Co., Ltd. It details the meeting held on March 26, 2021, including the approval of various reports such as the 2020 Supervisory Board Work Report, 2020 Financial Final Accounts Report, 2020 Profit Distribution Plan, Internal Control Self-Evaluation Report, and the 2020 Annual Report and its summary. The document also mentions that the 2020 Annual Report and summary were reviewed and approved by the Supervisory Board, confirming the report's compliance and accuracy. However, the document itself does not contain the full annual report or detailed financial statements but rather the resolutions and approvals related to these reports. The document length is 2516 characters, which is relatively short and consistent with an announcement or resolution rather than the full report. It also references that the full 2020 Supervisory Board Work Report is available on the CNINFO website, indicating this document is an announcement of approvals and resolutions rather than the report itself. Therefore, this document fits best as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially announces the resolutions and approvals made by the Supervisory Board that will be submitted to the shareholders' meeting for further approval.
2021-03-29 Chinese
金陵药业股份有限公司2020年度决算报告
Annual Report Classification · 95% confidence The document is titled as the 2020 annual financial settlement report of Jinling Pharmaceutical Co., Ltd. It includes detailed financial statements, analysis of assets, liabilities, equity, income, expenses, profit, and changes in accounting policies. It also mentions an audit report issued by an accounting firm, confirming the financial statements' compliance and fairness. The document contains comprehensive financial data for the full fiscal year 2020, including consolidated and parent company financials, changes in subsidiaries, and detailed financial ratios. The length is over 6,000 characters, indicating it is a full report rather than a brief announcement. These characteristics align with an Annual Report (10-K) filing, which covers the company's full financial performance and activities for the year. FY 2020
2021-03-29 Chinese
金陵药业股份有限公司2020年年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2020 Annual Board of Directors Work Report" of Jinling Pharmaceutical Co., Ltd. It details the board's activities, governance, internal control, compliance, and future plans for 2021. It includes information about board composition, committee activities, internal control audit results, and governance practices. The document references the 2020 annual report for detailed financial and operational analysis but itself is a narrative report on board work and governance rather than a full annual report or financial statements. The content aligns with a Management Reports (MDA) filing, which provides management's detailed explanation of company governance, business trends, and outlook. The document length is under 5,000 characters, but it is substantive and not merely an announcement or certification. Therefore, the appropriate classification is Management Reports (MDA).
2021-03-29 Chinese
金陵药业独立董事关于第八届董事会第七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to agenda items for the company's eighth board of directors' seventh meeting. It references proposals about hiring audit firms and internal control firms for the 2021 fiscal year and the execution of related party transactions for 2020. The document is short (699 characters) and consists mainly of independent directors' opinions and signatures, without containing any financial data or detailed audit results. It is not a full audit report or annual report but rather an internal governance document related to board meeting agenda items. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management activities.
2021-03-29 Chinese
金陵药业股份有限公司关于公司会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding a change in accounting policy related to the adoption of a new lease accounting standard effective January 1, 2021. It details the reasons for the change, the new accounting policies, and the impact on the company. The document includes statements from the board of directors, independent directors, and the supervisory board approving the change. The document is relatively short (2161 characters) and serves as a formal announcement of the accounting policy change rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for announcements that do not fit other specific categories and are not full reports themselves.
2021-03-29 Chinese
董事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 7th meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It includes voting results on various reports and proposals such as the 2020 President's Work Report, 2020 Board Work Report, 2020 Financial Final Accounts Report, 2020 Profit Distribution Plan, Internal Control Self-Evaluation Report, Social Responsibility Report, and other strategic and financial matters. The document repeatedly states that these reports will be submitted to the shareholders' meeting for approval and are available on the designated website and newspapers. The document is a formal announcement of board meeting decisions rather than the reports themselves. The length is 4254 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document is best classified as a Regulatory Filing (RNS) because it announces board meeting resolutions and references other reports but does not contain the full reports or detailed financial statements itself.
2021-03-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.